Drugs Xagena
European Commission approved Humira ( Adalimumab ) as a treatment for psoriatic arthritis and as first-line treatment of severe rheumatoid arthritis ( RA ) in Europe. The approval for psoriatic art ...
The FDA ( Food and Drug Administration ) has approved Humira ( Adalimumab ) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines ...
Tumour necrosis factor alpha ( TNF-alpha ) is a cellular protein produced by the immune system and is an important mediator of many diseases, including inflammatory arthritis and inflammatory bowel di ...
The NICE ( National Institute for Health and Clinical Excellence ) has published final guidance on the use of Rituximab ( Mabthera; US: Rituxan ) for the treatment of rheumatoid arthritis and Adalimum ...
Safety reviews of tumor necrosis factor-alpha ( TNF-a ) antagonists, Infliximab ( Remicade ), Etanercept ( Enbrel ), and Adalimumab ( Humira ) identified rare cases of serious skin reactions, includin ...
Tumor necrosis factor a ( TNF- alpha ) blockade has emerged as a useful therapy for collagen vascular diseases or graft-vs-host disease. Fungal infections complicating such therapy have been reported ...
The European Commission has approved Humira ( Adalimumab ) for the treatment of active moderate to severe hidradenitis suppurativa ( acne inverse ) in adults with an inadequate response to convention ...
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has granted a positive opinion for Humira ( Adalimumab ) for the treatment of non-infectious interm ...
The European Commission ( EC ) has granted marketing authorisation for Olumiant ( Baricitinib ) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid ar ...
The European Commission ( EC ) has granted marketing authorization for Hulio, a biosimilar to Humira ( Adalimumab ), for all indications. The authorization follows the adoption of a positive opinio ...
The European Commission ( EC ) has approved Skyrizi ( Risankizumab ) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Skyrizi ( 150 m ...
